Middle East & Africa Enzyme Replacement Therapy Market

The enzyme replacement therapy market in the Middle East & Africa is expected to grow from US$ 297.32 million in 2022 to US$ 386.56 million by 2028; it is estimated to grow at a CAGR of 4.5% from 2022 to 2028.

Rising Prevalence of Lysosomal Storage Diseases (LSDs)

The leading cause of lysosomal storage diseases (LSDs) is mutations in the genes responsible for encoding a lysosomal enzyme. LSDs are characterized as an inborn metabolism error that results in an enzyme's absence or deficiency. Infants and children suffer are prone to LSDs as children can inherit the defective gene from one or both parents. However, since the last decade, the pattern has been changing, and LSDs are more common in adults. LSDs can lead to approximately 70 ailments, including Gaucher disease, Niemann-Pick disease, Fabry disease, Tay-Sachs disease, Mucopolysaccharidoses (MPS) diseases, and Pompe disease. These disorders are individually rare, but collectively they are significantly prevalent and affect 1 in 5,000 live births. There are limited treatments for many of LSDs. However, progress is being made in terms of therapies and treatments available for a few LSDs, thereby significantly improving the quality of life for those affected. For instance, enzyme replacement therapy has proven effective for individuals with Gaucher disease type I, II, and III. Enzyme replacement therapy helps improve anemia symptoms, low platelet counts, and skeletal issues and helps reduce liver and spleen enlargement. Thus, the rising prevalence of LSDs and limited therapies to cure the disease are driving the growth of the enzyme replacement therapy market in the Middle East & Africa.

Market Overview

The Middle East & Africa enzyme replacement therapy market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia was this region's largest enzyme replacement therapy market in 2021. According to an article published in the Journal of Applied Hematology in 2020, the prevalence is higher than currently reported in the available literature. This might be mainly due to the high percentage of consanguinity, especially among tribes. Gaucher disease is underdiagnosed in Saudi Arabia. It is sometimes misdiagnosed with other hematological disorders. Additionally, according to the same study mentioned above, in Saudi Arabia, around 75 patients have been diagnosed with Gaucher disease; however, there is a huge under-diagnosis or misdiagnosis gap for Gaucher disease. The incidence is expected to be much higher due to high consanguinity and a high pregnancy rate per family. Enzyme replacement therapy (ERT) is an effective treatment of Gaucher disease. A body of evidence from the Gaucher registry, sponsored by the International Collaborative Gaucher Group (ICGG), indicates that enzyme replacement therapy reverses both visceral and hematological manifestations of Gaucher disease and relieves skeletal symptoms, leading to a better quality of life. Further, the Government of Saudi Arabia launched the Saudi Vision 2030 program to reduce oil dependence and diversify other sectors, including healthcare, which is leading to the significant development in healthcare services and the high adoption rate of advanced technologies. Under the vision, universities from Saudi Arabia have contributed 93% of the national scientific research output, boosting the Ministry of Education's efforts to promote the research and innovation system. Moreover, pharmaceutical R&D and clinical trials play an essential role in improving healthcare, directly benefiting patients, and making the latest and greatest pharmaceutical industry advancements available and accessible to a broader pool of patients in Saudi Arabia. Thus, above discussed factors are boosting the growth of the enzyme replacement therapy market in Saudi Arabia.

 Middle East & Africa Enzyme Replacement Therapy Market Revenue and Forecast to 2028 (US$ Million)

Middle East & Africa Enzyme Replacement Therapy Strategic Insights

Strategic insights for the Middle East & Africa Enzyme Replacement Therapy provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Middle East & Africa Enzyme Replacement Therapy Report Scope

Middle East & Africa Enzyme Replacement Therapy Regional Insights

The geographic scope of the Middle East & Africa Enzyme Replacement Therapy refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

Middle East & Africa Enzyme Replacement Therapy Market Segmentation 

The Middle East & Africa enzyme replacement therapy market is segmented into enzyme type, therapeutic conditions, route of administration, end user, and country.

• Based on enzyme type, the market is segmented into alglucosidase alfa, agalsidase beta, imiglucerase, idursulfase, galsulfase, velaglucerase alfa, and other enzymes. The other enzymes segment registered the largest market share in 2022.
• By therapeutic conditions, the market is segmented into Gaucher's disease, Fabry's disease, MPS, Pompe's disease, SCID, and other therapeutic conditions. The Gaucher's disease segment held the largest market share in 2022.
• In terms of route of administration, the market is bifurcated into parenteral and oral. The parenteral segment held a larger market share in 2022.
• From end user point of reference, the market is segmented into hospitals, infusion centers, and others. The hospitals segment held the largest market share in 2022.

• Based on country, the market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the market in 2022.

Sanofi; BioMarine Pharmaceutical Inc; Takeda Pharmaceutical Company Limited; AbbVie Inc; Janssen Pharmaceutical (Johnson & Johnson Services, Inc.); Alexion Pharmaceutical, Inc. (AstaZeneca); Amicus Therapeutics; Recordati S.p.A; Recordati S.p.A; CHIESI farmaceutici S.p.A; and Pfizer Inc are among the leading companies operating in the enzyme replacement therapy market in the region.